The discovery of the JAK2 V617F mutation in the majority of patients with myelofibrosis (MF) has been followed by significant progress in drug development for MF, according to a recent review.

The authors note that ruxolitinib significantly reduces splenomegaly and improves symptom burden in MF patients. They also:

• Review advances in the understanding of the underlying disease biology, prognostic assessment, and therapeutic modalities for MF.
• Provide clinical trial evidence supporting the use of ruxolitinib, erythropoiesis stimulating agents, androgens, immunomodulatory drugs, interferon, cytoreductive drugs, and hypomethylating agents in MF.
• Present therapeutic options, including the new JAK1/2 inhibitors, and ruxolitinib-based combination approaches.